3Suppliers
11Customers
1Debt Items
20Related Chains

Elanco Animal Health Incorporated Suppliers

TickerNameConfidenceEvidence
AHV-INTERNATIONAL-B-V AHV-INTERNATIONAL-B-V 85% On April 30, 2026, we completed the previously announced acquisition of 100 % of the outstanding equity interests of AHV International B.V. (AHV)
MRK Merck & Co., Inc. 72% utical production processes are complex, highly regulated and can vary widely from product to product. Shifting or adding manufacturing capacity can be a lengthy process requiring significant capital…
MRK Merck & Co., Inc. 72% Reciprocal relationship from MRK graph: net sales of MK-1045, if approved. In July 2024, Merck acquired the aqua business of Elanco Animal Health Incorporated (Elanco aqua business) for total conside…

Elanco Animal Health Incorporated Customers

TickerNameConfidenceEvidence
BX Blackstone Inc. 92% Reciprocal relationship from BX graph: Reciprocal relationship from ELAN graph: Reciprocal relationship from BX graph: Reciprocal relationship from ELAN graph: In May 2025, we executed a Purchase and…
BX Blackstone Inc. 92% In May 2025, we executed a Purchase and Sale Agreement (PSA) with funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance (collectively, Blackstone).
TARSUS-PHARMACEUTICALS-INC TARSUS-PHARMACEUTICALS-INC 90% These payments are made by Tarsus to Blackstone through a third-party escrow account
LLY Eli Lilly and Company 72% services to prevent and treat disease in farm animals and pets. We partner with farmers, pet owners, veterinarians and society to create value and help our customers improve the health of animals in …
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from ELAN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ELAN graph: Reciprocal relationship from LLY grap…
MRK Merck & Co., Inc. 72% Reciprocal relationship from MRK graph: Reciprocal relationship from ELAN graph: utical production processes are complex, highly regulated and can vary widely from product to product. Shifting or add…
MRK Merck & Co., Inc. 72% utical production processes are complex, highly regulated and can vary widely from product to product. Shifting or adding manufacturing capacity can be a lengthy process requiring significant capital…
BEXCAFE-LLC BEXCAFE-LLC 62% isting nutritional health offerings and further our efforts to explore innovative antibiotic alternatives. The composition of the purchase price was as follows: Up-front cash consideration $ 16 Defer…
BUSINESS-OVERVIEW-ELANCO-ANIMAL-HEALTH-INCORPORA BUSINESS-OVERVIEW-ELANCO-ANIMAL-HEALTH-INCORPORA 62% law. 5 Table of Contents PART I ITEM 1. BUSINESS Overview Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a global leader in animal healt…
NUTRIQUEST-LLC NUTRIQUEST-LLC 62% 22 United States $ 2,036 $ 1,983 $ 1,965 International 2,403 2,434 2,446 Revenue $ 4,439 $ 4,417 $ 4,411 We have a single customer that accounted for approximately 11 %, 10 % and 11 % of revenue for …
TRIRX-SPEKE-LTD TRIRX-SPEKE-LTD 62% 22 United States $ 2,036 $ 1,983 $ 1,965 International 2,403 2,434 2,446 Revenue $ 4,439 $ 4,417 $ 4,411 We have a single customer that accounted for approximately 11 %, 10 % and 11 % of revenue for …

Elanco Animal Health Incorporated Debt Obligations

InstrumentDescriptionConfidenceEvidence
ELAN-DEBT Debt stack $4.3B 90% Market cache reports total debt of $4.3B.

Elanco Animal Health Incorporated Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Elanco Animal Health Incorporated.

Elanco Animal Health Incorporated Ownership

HolderNameConfidenceEvidence
ELAN-OWNER-DODGE-COX Dodge & Cox 90% 13F overlay lists Dodge & Cox as top holder; 519 tracked holders.

Elanco Animal Health Incorporated Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
VEEV Veeva Systems Inc. 100.00 2
CRIS Curis, Inc. 100.00 2
ALEC Alector, Inc. 100.00 2
VNDA Vanda Pharmaceuticals Inc. 100.00 2
ACIU AC Immune SA 100.00 2
FDMT 4D Molecular Therapeutics, Inc. 100.00 2
AKTS Aktis Oncology, Inc. 100.00 2
NVO Novo Nordisk A/S 100.00 2
SDGR Schrödinger, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
BYSI BeyondSpring Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
ACRS Aclaris Therapeutics, Inc. 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
IMNM Immunome, Inc. 100.00 2